Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 16

1.

Human monoclonal antibodies targeting carbonic anhydrase IX for the molecular imaging of hypoxic regions in solid tumours.

Ahlskog JK, Schliemann C, Mårlind J, Qureshi U, Ammar A, Pedley RB, Neri D.

Br J Cancer. 2009 Aug 18;101(4):645-57. doi: 10.1038/sj.bjc.6605200. Epub 2009 Jul 21.

2.

Investigation of hypoxia and carbonic anhydrase IX expression in a renal cell carcinoma xenograft model with oxygen tension measurements and ¹²⁴I-cG250 PET/CT.

Lawrentschuk N, Lee FT, Jones G, Rigopoulos A, Mountain A, O'Keefe G, Papenfuss AT, Bolton DM, Davis ID, Scott AM.

Urol Oncol. 2011 Jul-Aug;29(4):411-20. doi: 10.1016/j.urolonc.2009.03.028. Epub 2009 Jun 12.

PMID:
19523858
3.

Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial.

Divgi CR, Pandit-Taskar N, Jungbluth AA, Reuter VE, Gönen M, Ruan S, Pierre C, Nagel A, Pryma DA, Humm J, Larson SM, Old LJ, Russo P.

Lancet Oncol. 2007 Apr;8(4):304-10.

PMID:
17395103
4.

Chemotherapy in the primary treatment of cervical carcinoma.

Serkies K, Jassem J.

Crit Rev Oncol Hematol. 2005 Jun;54(3):197-208. Review.

PMID:
15890269
5.

Hypoxia and anemia: effects on tumor biology and treatment resistance.

Vaupel P, Mayer A.

Transfus Clin Biol. 2005 Feb;12(1):5-10. Review.

PMID:
15814285
6.

G250: a carbonic anhydrase IX monoclonal antibody.

Lam JS, Pantuck AJ, Belldegrun AS, Figlin RA.

Curr Oncol Rep. 2005 Mar;7(2):109-15. Review.

PMID:
15717944
7.

Imaging hypoxia and angiogenesis in tumors.

Rajendran JG, Krohn KA.

Radiol Clin North Am. 2005 Jan;43(1):169-87. Review.

PMID:
15693655
8.

Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response.

Vaupel P, Harrison L.

Oncologist. 2004;9 Suppl 5:4-9. Review.

9.

Functional imaging of intratumoral hypoxia.

Foo SS, Abbott DF, Lawrentschuk N, Scott AM.

Mol Imaging Biol. 2004 Sep-Oct;6(5):291-305. Review.

PMID:
15380739
10.

Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report.

Dehdashti F, Grigsby PW, Mintun MA, Lewis JS, Siegel BA, Welch MJ.

Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1233-8.

PMID:
12654432
11.

Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix.

Loncaster JA, Harris AL, Davidson SE, Logue JP, Hunter RD, Wycoff CC, Pastorek J, Ratcliffe PJ, Stratford IJ, West CM.

Cancer Res. 2001 Sep 1;61(17):6394-9.

12.

Measuring Tumor Hypoxia.

Raleigh JA, Dewhirst MW, Thrall DE.

Semin Radiat Oncol. 1996 Jan;6(1):37-45.

PMID:
10717160
13.

Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250.

Grabmaier K, Vissers JL, De Weijert MC, Oosterwijk-Wakka JC, Van Bokhoven A, Brakenhoff RH, Noessner E, Mulders PA, Merkx G, Figdor CG, Adema GJ, Oosterwijk E.

Int J Cancer. 2000 Mar 15;85(6):865-70.

14.

Radiolabeled monoclonal antibody G250 in renal-cell carcinoma.

Oosterwijk E, Debruyne FM.

World J Urol. 1995;13(3):186-90.

PMID:
7550393
15.
16.

Hypoxic sensitizers--implications for radiation therapy.

Chapman JD.

N Engl J Med. 1979 Dec 27;301(26):1429-32. Review. No abstract available.

PMID:
229413

Supplemental Content

Support Center